anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a new compound useful as an antibacterial agent or its intermediate. SOLUTION: The objective compound is a cleavage product of a phosphoglycolipid antibiotic substance of the formula I (R<1> is H; R<2> is a 5-55C alkyl). A cultured product of Bacillus DSM 4675 or its processed product, especially a separated enzyme is usable for the decomposition of a phosphoglycolipid antibiotic substance, especially antibiotic substances of moenomycin group. Moenomycin A is incubated with moenomycinase preferably at pH 8.2-8.3 and 49-51 deg.C to obtain the compounds of the formula II and III and the compound of the formula III is incubated with an MBase preferably at pH 6-8 and 35-37 deg.C for 24 hr to obtain the compound of the formula IV. The reaction product can be used as an antibiotic substance (e.g. the compound of the formula III) or a basic unit (e.g. the compound of the formula II and IV) in the synthesis of a transglycosylase inhibitor.
Patients undergo 3D-CRT as in arm I. Patients also receive placebo PO BID on days 1-43 and carboplatin and paclitaxel as in Phase I. Within 4-6 weeks after completion of chemotherapy and radiation therapy, patients receive placebo on days 1-7 and carboplatin and paclitaxel as in Phase I.
The invention provides a method for inhibiting proliferation and inducing apoptosis of cancer cells, which inhibits the proliferation and induces the apoptosis of the cancer cells by using the siRNA of the targeted transportation gene of a protamine polypeptide fusion protein which is a single-chain fragment antibody. The invention also provides the protamine polypeptide fusion protein and a medicament for inhibiting the proliferation and inducing the apoptosis of the cancer cells. The fusion protein can inhibit the proliferation and induce the apoptosis of the cancer cells. The medicament contains an effective amount of the fusion protein and the siRNA of a tumor gene. In the invention, the siRNA of the tumor gene can be transferred to a specific cell population needing gene silencing to improve treatment effect, the RNAi has high pertinence, and the gene silencing effect is improved with the reduction in side effects. It is expected to block the expression of a cancer gene on a genetic level, destruct the proliferation of the cancer cells and a transfer signal transmission mechanism radically, and improve the sensitivity of the cancer cells to chemotherapeutics.
In our study, the CAD was defined by one of the following criteria: (1) based on World Health Organization criteria in terms of elevations of cardiac enzymes, electrocardiography (ECG) and clinical symptoms (angina, chest pressure, or shortness of breath); (2) angiographic evidence of more than 50% stenosis in one or more major coronary arteries; (3) previous history of PCI (percutaneous coronary intervention) or CABG (coronary artery bypass graft). The controls were selected from the two medical centers meeting the following criteria: (1) with no family history for CAD; (2) no clinical symptoms for CAD; (3) resting ECG showed normal results. The subjects with two or more risk factors of CAD (age\>45 for man and \>55 for woman, hypertension, diabetes, overweight, hyperlipidemia) were subjected to treadmill stress test and selected as controls if their ECG were normal without clinical symptoms. Those with history of cardiomyopathy, valvular disease, peripheral vascular disease, stroke, severe hepatic and kidney deficiency were excluded in our study.

Venous blood was collected by standard vein puncture in fasting condition. Four single-nucleotide polymorphisms (SNPs) (rs7586970, rs6434222, rs10153820 and rs8176528) were detected with polymerase chain reaction-direct sequencing method. And the genotypes of these SNPs were determined in both CAD patients and non-CAD controls.
Gravidin is a protein described as: inhibiting biosynthesis of arachidonic acid (acting on phospholipase A2), occurring in amniotic fluid, blood and particularly pre-term chorionic tissues, having an MW = 80 Kilodaltons and a pI of 8.6, having an N-terminal sequence of K-S-P-I-F-G-P-E-E-V and being homologous to Secretory Component. Discovery of the role of gravidin in pregnancy has led to: bioassays and immunoassays for serum gravidin, providing an improved method for predicting pregnancy-induced hypertension (PIH) in humans and animals. Excess gravidin appears to raise synthesis rates of the vasoconstrictor thromboxane A2 while lowering the vasodilator prostacyclin (PGII2). Methods for making assay reagents and pharmaceuticals, such as purified gravidin (or biologically active fragments of gravidin) and anti-gravidin antibodies have been developed. Gravidin may be harvested from tissue, milk, or other fluids, or manufactured by biotechnology after gene manipulation. Medical treatment with fragments or complete molecules of gravidin, or antagonists of gravidin includes anti-inflammatory actions, anti-PIH actions, and the prevention and treatment of cancer are provided.
There is no known specific treatment for overdose with lamivudine and zidovudine. If overdose occurs, the patient should be monitored and standard supportive treatment applied as required.

Lamivudine

Because a negligible amount of lamivudine was removed via (4-hour) hemodialysis, continuous ambulatory peritoneal dialysis, and automated peritoneal dialysis, it is not known if continuous hemodialysis would provide clinical benefit in a lamivudine overdose event.

Zidovudine

Acute overdoses of zidovudine have been reported in pediatric patients and adults. These involved exposures up to 50 grams. No specific symptoms or signs have been identified following acute overdosage with zidovudine apart from those listed as adverse events such as fatigue, headache, vomiting, and occasional reports of hematological disturbances. Patients recovered without permanent sequelae. Hemodialysis and peritoneal dialysis appear to have a negligible effect on the removal of zidovudine, while elimination of its primary metabolite, 3'-­azido-3’-deoxy-5’-O-β-D-glucopyranuronosylthymidine (GZDV), is enhanced.
The present invention relates to the medical field. In a first aspect the present invention relates to novel water soluble cyclodextrin-curcumin complexes having a pharmacological activity, in particular an anti-tumour and/or anti-inflammatory activity, and improved physico-chemical properties. In a second aspect, the present invention relates to a method for preparation of said water soluble curcumin derivatives. The invention further relates in a third aspect to a pharmaceutical composition comprising an effective amount of said water soluble curcumin derivatives. In a fourth aspect, the present invention concerns the use of said water soluble cucumin derivatives as a medicament and the use of said water soluble curcumin derivatives for the preparation of a medicament for the treatment of cancer and inflammatory diseases. In a fifth aspect, the present invention relates to the use of a pharmaceutical composition comprising said water soluble curcumin derivatives in the treatment of cancer and inflammatory diseases and to a new pharmaceutical composition comprising said water soluble curcumin derivatives.
PURPOSE: A cosmetic composition containing an extract of Bletilla striata, Perilla ocymoides, Echinacea purpurea and fermented soybean is provided. It exhibits antimicrobial effect, moisturizing effect, anti-inflammatory effect and free radical-scavenging effect and thus is expected to be helpful in healing atopic dermatitis. CONSTITUTION: The cosmetic composition contains 0.0001 to 30.0% by weight of herbal extract, based on the total weight of the composition. The herbal extract is prepared by mixing Bletilla striata Reichb. fil., Perilla ocymoides, Echinacea purpurea and fermented soybean in a weight ratio of 2 to 30:1 to 25:1 to 25:6 to 35 and then extracting in an organic solvent or a mixed solvent of the organic solvent and water. The organic solvent is selected from ethanol, methanol, propanol, butanol, glycerin, propylene glycol and butylene glycol.
The invention relates to medicine, in particular to vascular surgery and hepatology, and can be used for endovascular treatment of portal vein thrombosis in patients with liver cirrhosis.Summary of the invention consists in that an approach is performed in the subumbilical region with the introduction of an optical device and an approach under the edge of the left costal arch, in the projection of the spleen, with the introduction of a trocar of a diameter of 5 mm, through which, under visualization with the optical device, is introduced a needle with a blunt end, of a length of 15…20 cm and a diameter of 2…3 mm, which is introduced into the parenchyma of the spleen. Then, a contrast agent is introduced through the needle and, under X-ray control, the needle is introduced into an intrasplenic venous branch. Through the said needle is introduced a catheter on a guide, which passes through said venous branch, then through the splenic vein and portal vein, to the area of thrombus localization. After that, the guide is removed and are aspirated thrombotic masses, and through the catheter are introduced thrombolytic and anticoagulant drugs. Then the catheter is pulled up to the level of the hilum of the spleen, and simultaneously with its extraction, two components of fibrin glue are introduced through the formed canal, namely the first component comprises a fibrinogen solution 15…45 mg, and the second component comprises a mixture of thrombin solution 25…100 IU, 10% albumin solution 10…20 ml, aprotinin solution 250…1000 CIE and Ca2+ chloride solution 15…30 µmol, with filling of the canal in the spleen parenchyma. The catheter is then removed and the wound is sutured.
The MyCaRe mobile application (education and symptom monitoring which includes pain, mood scales, wound monitoring) and Fitbit accelerometer (steps walked, distance) will be provided to patients receiving intervention group allocation for the initial 6 to 8 weeks recovery post cardiac surgery. The patients will be provided a temporary loan mobile device loaded with MyCaRe and Fitbit Inspire 2 before leaving hospital. They will be asked to input data (pain, mood, wounds, activity, blood sugar, blood pressure) daily if possible in first 2 weeks and once weekly thereafter until 6 to 8 weeks or until entry to a cardiac rehabilitation program.
Microbial metabolites have been indicated to communicate with the host's endocrine system, regulating hormone production, immune-endocrine communications, and interactions along the gut-brain axis, eventually affecting the occurrence of endocrine cancer. Furthermore, microbiota metabolites such as short-chain fatty acids (SCFAs) have been found to affect the tumor microenvironment and boost immunity against tumors. SCFAs, including butyrate and acetate, have been demonstrated to exert anti-proliferative and anti-protective activity on pancreatic cancer cells. The employing of microbial metabolic products in conjunction with radiation and chemotherapy has shown promising outcomes in terms of reducing treatment side effects and boosting effectiveness. Certain metabolites, such as valerate and butyrate, have been made known to improve the efficiency of CAR T-cell treatment, whilst others, such as indole-derived tryptophan metabolites, have been shown to inhibit tumor immunity. This review explores the intricate interplay between microbial metabolites and endocrine tumorigenesis, spanning mechanistic insights to the discovery of potential therapeutic biomarkers.
Glioma, a type of brain tumor, is influenced by mechanical forces in its microenvironment that affect cancer progression. However, our understanding of the contribution of compression and its associated mechanisms remains limited. The objective of the present study was to create an environment in which human brain glioma H4 cells experience pressure and thereby investigate the compressive mechanosensors and signaling pathways. Subsequent time‑lapse imaging and wound healing assays confirmed that 12 h of compression significantly increased cell migration, thereby linking compression with enhanced cell motility. Compression upregulated the expression of Piezo1, a mechanosensitive ion channel, and growth differentiation factor 15 (GDF15), a TGF‑β superfamily member. Knockdown experiments targeting PIEZO1 or GDF15 using small interfering RNA resulted in reduced cell motility, with Piezo1 regulating GDF15 expression. Compression also upregulated CTLA4, a critical immune checkpoint protein. The findings of the present study therefore suggest that compression enhances glioma progression by stimulating Piezo1, promoting GDF15 expression and increasing CTLA4 expression. Thus, these findings provide important insights into the influence of mechanical compression on glioma progression and highlight the involvement of the Piezo1‑GDF15 signaling pathway. Understanding tumor responses to mechanical forces in the brain microenvironment may guide the development of targeted therapeutic strategies to mitigate tumor progression and improve patient outcomes.
Patients receive nivolumab IV on day 1 of all cycles and ipilimumab IV over 30 minutes on day 1 of cycles 1-4. Cycles repeat every 21 days for 4 cycles and then every 28 days in the absence of disease progression or unacceptable toxicity.
The experimental group participates in once weekly group music therapy session for 6 weeks using playing of simple wind instruments, singing, and music visualization. The Music therapy session lasts 45 min. and encourages patients to use breathing techniques to achieve a relaxation response. Extructured techniques involving singing, music improvisation supports breath pattens and provides supporting coping styles. The use of wind instruments involves a focus of breathing efficiently and elongating the exhalation to prolong musical tones and transferring breath control. Music Visualization involving deep breathing techniques provides optimal mind-body connection, influences breathing rhythms through more indirect means while reducing stress, accessing altered states and encourages healing imagery.
FIELD: food industry. ^ SUBSTANCE: invention is related to alimentary therapy. Proposed is a method providing for a cancer patient long-term alimentation and envisaging long-term administration of a nutritional product to the patient through a probe, the product containing a protein source providing for 14-25% of the product energy value and composed of whey (50% of energy value), glutamine (0.5% - 10% of energy value), leucine (0.8% - 3.5% of energy value), a carbohydrate source (20-55% of the product energy value) and a lipid source ( 25-40% of the product energy value). Optionally, the method envisages first administration of the above composition to a tumour cancer patient (through a probe) and then, upon normal metabolic status recovery - administration of a second composition for long-term alimentation that differs from the first composition in terms of formulation. Optionally, the method providing for a cancer patient long-term alimentation envisages administration of glutamine together with the above nutritional composition at least a week prior to commencement of the cancer therapy course. ^ EFFECT: invention enables to ensure well-balanced and efficient long-term through-probe alimentation of a cancer patient. ^ 36 cl, 4 ex
Participants will receive VOLITE XC for initial treatment and followed for up to 14 Months. Participants will have the opportunity to receive optional touch-up and optional repeat treatment of VOLITE XC during the follow-up duration period.
PURPOSE: A composition containing hordenine as an active ingredient is provided to produce a pharmaceutical product and a food composition with stability, which improves anti-wrinkling and skin whitening, promotes hair growth, and prevents alopecia. CONSTITUTION: A composition for improving skin conditions contains hordenine as an active ingredient. A composition for suppressing inflammation contains hordenine as an active ingredient. A composition for antioxidation contains hordenine as an active ingredient. The improvement of skin conditions includes anti-wrinkling, skin whitening, hair growth, or alopecia prevention. The composition additionally contains propafenone.
INTRODUCTION: Left bundle branch pacing (LBBP) is a physiological pacing modality. However, the long procedure and fluoroscopy time of LBBP is still a problem. This study aims to compare the clinical outcomes between transthoracic echocardiography (TTE)- and X-ray-guided LBBP.
METHODS: This is a single-center, prospective, randomized controlled study. Consecutive patients who underwent LBBP in our team from June 2022 to November 2022 were enrolled. Procedure and fluoroscopy time, pacing parameters, electrophysiological and echocardiographic characteristics, as well as complications were recorded at implantation and during follow-up.
RESULTS: In this study, 60 patients were enrolled and divided into two groups: 30 patients were allocated to the X-ray group and the remaining 30 to the TTE group. There was no significant difference in the success rate between the two groups (86.7% vs. 76.7%, p = .317). The procedure time of TTE group was comparable to that of the X-ray group (9.0 vs. 12.0 min, p = .063). However, the fluoroscopy time in the TTE group was significantly lower than that of the X-ray group (2.5 vs. 5.0 min, p = .002). There were no statistically significant differences in pacing parameters, electrophysiological and echocardiographic characteristics, or complications between the two groups at implantation and during follow-up.
CONCLUSION: TTE-guided LBBP is a feasible and safe method. Compared with X-ray, TTE showed a comparable success rate and procedure time, but it could significantly reduce the fluoroscopy time of LBBP.
The invention discloses an alcohol disinfectant containing a hemp extract and a preparation method thereof, belonging to the field of medicines. The composition comprises the following raw and auxiliary materials in parts by weight: 48-76 parts of ethanol; 5-40 parts of distilled water; 0.1-15 parts of a hemp extract; 0.01-0.5 parts of essence. The alcohol disinfectant liquid contains active components of cannabis extract, has strong pain relieving and anti-inflammatory effects on skin wound, can reduce pain caused by stimulation of alcohol on wound, and is helpful for wound healing. Meanwhile, the hemp extract can form a protective film on the surface of an object and skin after the ethanol volatilizes, and can play a role in sterilizing and preventing for a long time. The formula of the disinfectant also adds a certain amount of plant essence, so that the pungent smell of alcohol is effectively improved. The method has the advantages of simple process, easily obtained raw materials and low cost, and is suitable for industrial production.
The Group Lifestyle Balance program is a direct adaptation of the Diabetes Prevention Program lifestyle intervention. Participants in the study choose traditional GLB face-to-face group delivery or delivery via DVD. Group members met weekly and completed the program over a 12-15 week period. The face-to-face group meetings were led by a trained lifestyle coach, and participants were encouraged to self-monitor their eating and physical activity behaviors. Participants in both intervention delivery modes received a GLB workbook, fat and calorie counter, pedometer, and self-monitoring books for tracking food intake and physical activity.
The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 4 ng/ml remifentanil.
Aim: Our goal was to explore the prognostic value of the neutrophil-to-hemoglobin ratio (NHR) in HBV-related decompensated cirrhosis (HBV-DC) patients. Methods: 172 HBV-DC patients were enrolled. Multivariate analyses were used to identify risk factors influencing 30-day mortality. Results: The 30-day mortality was 12.8% (22/172). nonsurvivors exhibited a higher NHR than survivors. On multivariate analysis, NHR and model for end-stage liver disease (MELD) score were the only independent predictors of mortality. Notably, the predictive capabilities of NHR were found to be comparable to those of the MELD score. Conclusion: High NHR was associated with poor prognosis in HBV-DC patients, and NHR can serve as an effective and readily available indicator for the prediction of mortality in these patients.
This study will be performed at six large hospitals in Lebanon in the three largest cities Beirut, Tripoli, and Saida. The study will enroll children younger than 5 years of age who are admitted to the hospital because of gastroenteritis. Enrollment will continue for a period of two years at each hospital. Inclusion criteria are age \< 5 years, with gastroenteritis as the main reason for admission to the hospital or for a stay in the Emergency Department longer than 12 hours. Exclusion criteria include onset of symptoms beyond 12 hours of admission (health-care associated infection). For all enrolled subjects, data will be collected about severity of illness, outcome, and history of vaccination. Stool samples will be collected for genotyping of rotavirus.
BACKGROUND: For the treatment of von Willebrand disease (VWD), von Willebrand factor (VWF) concentrates can be used in on-demand, long-term prophylaxis, and surgical prophylaxis regimens.
METHODS: This systematic literature review was conducted to evaluate the efficacy, consumption, and safety of plasma-derived human coagulation FVIII/human VWF (pdVWF/FVIII; Voncento/Biostate) for the treatment of patients with any inherited VWD type. An electronic search was conducted in MEDLINE and Cochrane Library databases on VWD therapies. All retrieved publications were assessed against predefined inclusion/exclusion criteria following the Cochrane group recommendations. Associated pharmacovigilance data were collected across the same time period.
RESULTS: Eleven publications from eight study cohorts were identified for data retrieval. All were from multicenter studies and included both pediatric and adult patients. Eight publications included evaluations of the efficacy of pdVWF/FVIII for on-demand treatment, eight included long-term prophylactic treatment, and eight included surgical prophylaxis. Treatment protocols and VWF administration methods differed between studies, as did safety evaluations. The clinical response was rated as excellent/good for on-demand treatment in 66 to 100% of nonsurgical bleeds, 89 to 100% in the treatment of breakthrough bleeds during long-term prophylaxis treatment, and hemostatic efficacy in surgical procedures was 75 to 100%. Pharmacovigilance data confirmed a low incidence of adverse events in treated patients.
CONCLUSION: This review provides a comprehensive summary of studies that evaluated the use of pdVWF/FVIII in VWD demonstrating the long-term effectiveness and safety of this pdVWF/FVIII across all ages, types of VWD, and treatment settings.
The present invention provides a medicine for regulating a nervous system and treating epilepsy. The medicine contains medicinal or edible auxiliary materials and medicine effective components and is prepared into a preparation which can be accepted by the medicament. The present invention is characterized in that the effective component of the medicine is each minimum preparation unit contains 20 to 150 mg of qingyangshengan and 30 to 200 mg of helicidum. The present invention can solve the defect of poor biological availability of compounds of qingyangshengan type a helicidum type. Research indicates that the biological availability, the activity and the target performance of the medicine of the composition of qingyangshengan and helicidum are better than those of an ordinary oral preparation containing a single component, and the medicine of the present invention can realize slow release and change the adverse reaction, such as stimulation, etc. of the medicine to gstrointestinal tracts. The scheme adopts superfined qingyangshengan and helicidum, which increases the specific surface area, is easy to contact intestinal walls, accelerates the absorption of a human body and shows specific medicine efficiency.